Chronic Pain Associated with Painful Diabetic Neuropathy Market Sees is Predicted to Surge During the Forecast Period (2025–2034) with New Treatment Innovations and Expanding Research Spending | DelveInsight
According to DelveInsight’s analysis, the market for chronic pain associated with painful diabetic neuropathy is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as JOURNAVX, Adezunap, Cebranopadol, and others, and healthcare spending in the 7MM.
New York, USA, July 31, 2025 (GLOBE NEWSWIRE) -- Chronic Pain Associated with Painful Diabetic Neuropathy Market Sees is Predicted to Surge During the Forecast Period (2025–2034) with New Treatment Innovations and Expanding Research Spending | DelveInsight
According to DelveInsight’s analysis, the market for chronic pain associated with painful diabetic neuropathy is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as JOURNAVX, Adezunap, Cebranopadol, and others, and healthcare spending in the 7MM.
DelveInsight’s Chronic Pain Associated with Painful Diabetic Neuropathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging chronic pain associated with painful diabetic neuropathy drugs, market share of individual therapies, and current and forecasted chronic pain associated with painful diabetic neuropathy market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Chronic Pain Associated with Painful Diabetic Neuropathy Market Report
- According to DelveInsight’s analysis, the total chronic pain associated with painful diabetic neuropathy market size is expected to grow positively by 2034.
- The United States accounts for the largest market size of chronic pain associated with painful diabetic neuropathy, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
- In the United States, the prevalence of diabetic peripheral neuropathy among adolescents with type 1 diabetes was reported at 8.2%, indicating that neuropathic complications can emerge early in the disease course, even within a relatively young population.
- Prominent companies, including Vertex Pharmaceuticals, Tris Pharma, Apurano Pharmaceuticals, and others, are actively working on innovative chronic pain associated with painful diabetic neuropathy drugs.
- Some of the key chronic pain associated with painful diabetic neuropathy therapies in the pipeline include JOURNAVX (Suzetrigine), Adezunap (AP707), Cebranopadol (TRN-228), and others. These novel chronic pain associated with painful diabetic neuropathy therapies are anticipated to enter the chronic pain associated with painful diabetic neuropathy market in the forecast period and are expected to change the market.
Discover which chronic pain associated with painful diabetic neuropathy medications are expected to grab the market share @ Chronic Pain Associated with Painful Diabetic Neuropathy Market Report
Chronic Pain Associated with Painful Diabetic Neuropathy Overview
Chronic pain associated with painful diabetic neuropathy is a long-lasting condition, often described as burning or stabbing, that arises from nerve damage caused by diabetes. It commonly affects the legs and feet, leading to a substantial decline in quality of life and hindering daily activities.
The condition’s development is largely influenced by metabolic and vascular dysfunctions, such as increased levels of sorbitol and fructose, the buildup of advanced glycation end products (AGEs), heightened oxidative stress from reactive oxygen species, and activation of protein kinase C—which collectively contribute to nerve injury in diabetic individuals.
Diagnosing this type of chronic pain can be difficult. It is frequently underrecognized, particularly in the early or less severe stages, due to the subjective nature of pain perception and the absence of a clear-cut diagnostic test. Its symptoms often resemble those of other types of neuropathy, and inconsistent pain reporting among patients further complicates accurate diagnosis.
Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology Segmentation
The chronic pain associated with painful diabetic neuropathy epidemiology section provides insights into the historical and current chronic pain associated with painful diabetic neuropathy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The chronic pain associated with painful diabetic neuropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
- Diagnosed Prevalent Cases of Diabetic Neuropathy
- Type-specific Diagnosed Prevalent Cases of Diabetic Neuropathy
- Diagnosed Prevalent Cases of Painful Diabetic Neuropathy
- Diagnosed Prevalent Cases of Chronic Pain Associated with Painful Diabetic Neuropathy
Download the report to understand which factors are driving chronic pain associated with painful diabetic neuropathy epidemiology trends @ Chronic Pain Associated with Painful Diabetic Neuropathy Treatment Algorithm
Chronic Pain Associated with Painful Diabetic Neuropathy Treatment Market
The therapeutic approach to managing chronic pain from painful diabetic neuropathy (PDN) is gradually shifting, integrating both pharmacological and non-pharmacological interventions. Commonly used first-line drugs include anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants, while opioids such as tapentadol are typically reserved for more severe cases.
Complementary non-drug treatments like physical therapy, transcutaneous electrical nerve stimulation (TENS), and cognitive-behavioral therapy enhance the overall effectiveness of care. However, many patients still experience suboptimal pain relief, underscoring the need for continued research into innovative therapies that target specific pain pathways to achieve better safety, efficacy, and long-term outcomes in PDN management.
In August 2012, NUCYNTA was approved for treating neuropathic pain linked to diabetic peripheral neuropathy (DPN), representing a notable milestone in diabetic pain care. This centrally acting analgesic introduced a dual mechanism of action specifically designed to address the complex nature of neuropathic pain in DPN.
NUCYNTA (Tapentadol ER) is a synthetic, centrally acting analgesic indicated for severe, chronic pain requiring long-term opioid therapy when alternative treatments are insufficient. While its full mechanism of action is not completely defined, preclinical research suggests it works through a combination of mu-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI).
Learn more about the chronic pain associated with painful diabetic neuropathy treatment options @ Chronic Pain Associated with Painful Diabetic Neuropathy Treatment Guidelines
Chronic Pain Associated with Painful Diabetic Neuropathy Emerging Drugs and Companies
The treatment landscape for chronic painful diabetic neuropathy is evolving swiftly, with several pharmaceutical companies pushing forward new therapeutic candidates. Key companies like Vertex Pharmaceuticals (JOURNAVX), Tris Pharma (Cebranopadol), Apurano Pharmaceuticals (Adezunap), and others are at the forefront, dedicating significant efforts to develop innovative solutions for this challenging condition. Their continued R&D initiatives highlight a rising commitment to enhancing treatment options for patients grappling with the persistent pain of diabetic neuropathy.
Suzetrigine (also known as VX-548) is an oral, non-opioid drug developed for managing pain, particularly in conditions such as painful diabetic neuropathy. It works by selectively blocking the voltage-gated sodium channel NaV1.8, a crucial mediator in the transmission of pain signals through peripheral nerves. In 2024, Vertex Pharmaceuticals made significant progress in its clinical program by launching pivotal Phase III trials of suzetrigine for diabetic peripheral neuropathy (DPN), marking a key advancement in the development of novel pain therapies.
Adezunap, developed by Apurano Pharmaceuticals, is an experimental medication formulated as a sublingual (oromucosal) spray using nano-technology. Based on THC, it is designed for enhanced absorption and quick onset of action. Adezunap functions as a cannabinoid CB1 receptor agonist, targeting the endocannabinoid system to reduce pain transmission. The drug is currently in Phase III clinical trials for chronic painful diabetic polyneuropathy, reflecting ongoing efforts to evaluate its therapeutic effectiveness in this area.
Cebranopadol is a novel investigational agent that acts as a dual agonist at both the nociceptin/orphanin FQ peptide (NOP) receptor and the µ-opioid peptide (MOP) receptor. This dual mechanism allows it to modulate distinct pain pathways, offering potential benefits for treating moderate-to-severe pain and opioid use disorder (OUD). Encouraging clinical outcomes have been observed in diabetic neuropathic pain, with a favorable safety profile. According to the latest company pipeline, cebranopadol is in Phase II/III trials for chronic neuropathic pain and has successfully completed Phase II studies in diabetic neuropathy, showing promising efficacy.
The anticipated launch of these emerging chronic pain associated with painful diabetic neuropathy therapies are poised to transform the chronic pain associated with painful diabetic neuropathy market landscape in the coming years. As these cutting-edge chronic pain associated with painful diabetic neuropathy therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic pain associated with painful diabetic neuropathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for chronic pain associated with painful diabetic neuropathy, visit @ Chronic Pain Associated with Painful Diabetic Neuropathy Management
Chronic Pain Associated with Painful Diabetic Neuropathy Market Dynamics
The chronic pain associated with painful diabetic neuropathy market dynamics are anticipated to change in the coming years. The market for chronic pain associated with painful diabetic neuropathy is driven by a growing global diabetic population, increasing awareness of neuropathic complications, and the rising demand for non-opioid pain management options. As diabetes prevalence surges, particularly in aging populations and low-to-middle-income countries, the incidence of PDN is also escalating. This has prompted heightened clinical focus on effective and sustained pain relief.
Additionally, advancements in novel mechanisms of action, such as sodium channel blockers and monoclonal antibodies, along with favorable regulatory pathways for breakthrough therapies, are further accelerating market growth. Increased patient advocacy and improved diagnostic capabilities are also contributing to earlier intervention and broader treatment adoption.
Furthermore, many potential therapies are being investigated for the treatment of chronic pain associated with painful diabetic neuropathy, and it is safe to predict that the treatment space will significantly impact the chronic pain associated with painful diabetic neuropathy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the chronic pain associated with painful diabetic neuropathy market in the 7MM.
However, several factors may impede the growth of the chronic pain associated with painful diabetic neuropathy market. A major challenge lies in the complex pathophysiology of PDN, which varies significantly among patients, making it difficult to develop universally effective treatments. Additionally, current treatment options often provide only partial relief and are associated with side effects or limited tolerability, leading to low patient adherence. Regulatory hurdles and the need for long-term efficacy and safety data further delay the approval of novel therapies. Reimbursement restrictions and a lack of awareness or underdiagnosis of PDN also contribute to limited patient access and market uptake.
Moreover, chronic pain associated with painful diabetic neuropathy treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the chronic pain associated with painful diabetic neuropathy market growth may be offset by failures and discontinuation of emerging therapies.
| Chronic Pain Associated with Painful Diabetic Neuropathy Report Metrics | Details |
| Study Period | 2020–2034 |
| Chronic Pain Associated with Painful Diabetic Neuropathy Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Chronic Pain Associated with Painful Diabetic Neuropathy Companies | Vertex Pharmaceuticals, Tris Pharma, Apurano Pharmaceuticals, Collegium Pharmaceutical, and others |
| Key Chronic Pain Associated with Painful Diabetic Neuropathy Therapies | JOURNAVX (Suzetrigine), Adezunap (AP707), Cebranopadol (TRN-228), NUCYNTA, and others |
Scope of the Chronic Pain Associated with Painful Diabetic Neuropathy Market Report
- Chronic Pain Associated with Painful Diabetic Neuropathy Therapeutic Assessment: Chronic Pain Associated with Painful Diabetic Neuropathy current marketed and emerging therapies
- Chronic Pain Associated with Painful Diabetic Neuropathy Market Dynamics: Conjoint Analysis of Emerging Chronic Pain Associated with Painful Diabetic Neuropathy Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Associated with Painful Diabetic Neuropathy Market Access and Reimbursement
Discover more about chronic pain associated with painful diabetic neuropathy drugs in development @ Chronic Pain Associated with Painful Diabetic Neuropathy Clinical Trials
Table of Contents
| 1. | Chronic Pain Associated with Painful Diabetic Neuropathy Market Key Insights |
| 2. | Chronic Pain Associated with Painful Diabetic Neuropathy Market Report Introduction |
| 3. | Chronic Pain Associated with Painful Diabetic Neuropathy Market Overview at a Glance |
| 4. | Chronic Pain Associated with Painful Diabetic Neuropathy Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Chronic Pain Associated with Painful Diabetic Neuropathy Treatment and Management |
| 7. | Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Chronic Pain Associated with Painful Diabetic Neuropathy Marketed Drugs |
| 10. | Chronic Pain Associated with Painful Diabetic Neuropathy Emerging Drugs |
| 11. | Seven Major Chronic Pain Associated with Painful Diabetic Neuropathy Market Analysis |
| 12. | Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
Related Reports
Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, among others.
Diabetic Neuropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Vertex Pharmaceuticals Incorporated, Novaremed, Trevena, Inc., WinSanTor, Inc., Rigshospitalet, Denmark, Tris Pharma, Inc., Novo Nordisk A/S, JMackem Co., Ltd, Apurano Pharmaceuticals GmbH, Glenmark Pharmaceuticals, among others.
Diabetic Peripheral Neuropathy Market
Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic peripheral neuropathy Market companies, including Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Daiichi Sankyo, Inc., Avazzia, Inc., among others.
Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., among others.
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen, Novo Nordisk, Prevention Bio, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
